DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that MP-470 effectively sensitizes prostate and breast cancer cells to erlotinib (Abstract No. 671).
Entitled, "Inhibition of erlotinib resistance on HER-family tyrosine kinases by combination with MP-470, a multi-targeted TK inhibitor in prostate and breast cancer," the poster highlights data indicating that the combination of MP-470 and erlotinib inhibits the binding of the p85 subunit of PI3K, and has a greater impact than either agent alone in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and HER3.
"These data build upon previous results showing that MP-470 exhibits anti-tumor activity in breast and prostate cancer cells," said Dr. David Bearss, SuperGen's Vice President and Chief Scientist. "The fact that MP-470 in combination with erlotinib effectively suppressed the HER pathway suggests that concurrent administration of both compounds could represent a new treatment for prostate and breast cancers. We will continue to explore this synergy as we develop further MP-470."
Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site www.supergen.com.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
Forward-Looking Statements
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
SOURCE SuperGen Inc.
